Business
Hemogenyx Pharmaceuticals PLC Announces Second Patient Treated with HG-CT-1 CAR-T Therapy
LONDON, GB / ACCESS Newswire / May 2, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company's ongoing Phase I clinical trial of HG-CT-1, its proprietary ...
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"LONDON, GB / ACCESS Newswire / May 2, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company's ongoing Phase I clinical trial of HG-CT-1, its proprietary CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia ("R/R AML") in adults.","length":370,"tagName":"p"},{"type":"text","content":"This milestone follows the successful first-in-human treatment with HG-CT-1, which demonstrated a favorable initial safety profile with no adverse effects observed, and the subsequent recruitment of the second patient. Together, these milestones mark steady progress in the clinical development of HG-CT-1 and reinforce the Company's commitment to advancing treatment options for patients with limited therapeutic alternatives.","length":431,"tagName":"p"},{"type":"text","content":"The Phase I trial is a dose-escalation study designed to assess the safety profile of HG-CT-1 and to collect data on key secondary endpoints, including anti-leukemic activity, overall survival, progression-free survival, and duration of response.","length":246,"tagName":"p"},{"type":"text","content":"The Company believes that continued clinical execution will not only advance a potentially transformative treatment for adult patients with limited therapeutic options but also generate long-term value for shareholders by establishing HG-CT-1 as a platform-defining asset in the field of hematologic malignancies. While the current trial is focused on adult patients, successful initial outcomes would pave the way for a pediatric trial - an area of significant unmet medical need in AML, where few effective treatment options exist for children.","length":546,"tagName":"p"},{"type":"text","content":"Further updates on the clinical trial will be provided in due course.","length":69,"tagName":"p"},{"type":"text","content":"Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:","length":84,"tagName":"p"},{"type":"text","content":""The treatment of a second patient with HG-CT-1 marks another critical step in the development of our CAR-T therapy for relapsed or refractory AML. The ability to move forward with dosing reflects the capabilities of our scientific and manufacturing teams and further validates our pla...